Association of proton pump inhibitor use with the development of febrile neutropenia in lymphoma patients

References

• Klastersky J. Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis. 2004;39(Suppl 1):S32–7.
   PubMedGoogle Scholar
• Aapro MS, Bohlius J, Cameron DA, et al. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours. Eur J Cancer. 2011;47(1):8–32.
   PubMed Web of Science ®Google Scholar
• Pettengell R, Bosly A, Szucs TD, et al. Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU prospective observational European neutropenia study. Br J Haematol. 2009;144(5):677–685. .
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Infectious diseases society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011;52(4):e56–e93.
   PubMed Web of Science ®Google Scholar
• Sachs G, Shin JM, Howden CW. Review article: the clinical pharmacology of proton pump inhibitors. Ailment Pharmacol Ther. 2006;23(2):2–8.
   PubMedGoogle Scholar
• Ferrari S, Perut F, Fagioli F, et al. Proton pump inhibitor chemosensitization in human osteosarcoma: from the bench to the patients’ bed. J Transl Med. 2013;11:268.
   Web of Science ®Google Scholar
• Spugnini EP, Citro G, Fais S. Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy. J Exp Clin Cancer Res. 2010;29:44.
   PubMed Web of Science ®Google Scholar
• Zedtwitz-Liebenstein K, Wenisch C, Patruta S, et al. Omeprazole treatment diminishes intra-and extracellular neutrophil reactive oxygen production and bactericidal activity. Crit Care Med. 2002;30(5):1118–1122.
   PubMed Web of Science ®Google Scholar
• Dury S, Nardi J, Gozalo C, et al. Agranulocytosis induced by proton pump inhibitors. J Clin Gastroenterol. 2012;46(10):859.
   PubMed Web of Science ®Google Scholar
• Abramowitz J, Thakkar P, Isa A, et al. Adverse event reporting for proton pump inhibitor therapy: an overview of systematic reviews. Otolaryngol Head Neck Surg. 2016;155(4):547–554.
   PubMed Web of Science ®Google Scholar
• Yang YX, Lewis JD, Epstein S, et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006;296:2947–2953.
   PubMed Web of Science ®Google Scholar
• Laheij RJF, Sturkenboom MCJM, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292(16):1955–1960.
   PubMed Web of Science ®Google Scholar
• MacLaren R, Kassel LE, Kiser TH, et al. Proton pump inhibitors and histamine-2 receptor antagonists in the intensive care setting: focus on therapeutic and adverse events. Expert Opin Drug Safe. 2015;14(2):269–280.
   PubMed Web of Science ®Google Scholar
• Yu LY, Sun LN, Zhang XH, et al. A review of the novel application and potential adverse effects of proton pump inhibitors. Adv Ther. 2017;34(5):1070–1086. .
   PubMed Web of Science ®Google Scholar
• Freedberg DE, Toussaint NC, Chen SP, et al. Proton pump inhibitors alter specific taxa in the human gastrointestinal microbiome: a crossover trial. Gastroenterology. 2015;149(4):883–5.e9.
   PubMed Web of Science ®Google Scholar
• Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol. 2007;102(2047–2056):2047–2056.
   PubMedGoogle Scholar
• Barletta JF, Sclar DA. Proton pump inhibitors increase the risk for hospital-acquired Clostridium difficile infection in critically ill patients. Crit Care. 2014;18(6):714.
   PubMed Web of Science ®Google Scholar
• Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med. 2016;176(2):238–246.
   PubMed Web of Science ®Google Scholar
• Lambert AA, Lam JO, Paik JJ, et al. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One. 2015;10(6):e0128004.
   PubMed Web of Science ®Google Scholar
• McDonald EG, Milligan J, Frenette C, et al. Continuous proton pump inhibitor therapy and the associated risk of recurrent clostridium difficile infection. JAMA Intern Med. 2015;175(5):784–791.
   PubMed Web of Science ®Google Scholar
• Dos Santos-Schaller O, Boisset S, Seigneurin A, et al. Recurrence and death after Clostridium difficile infection: gender-dependant influence of proton pump inhibitor therapy. SpringerPlus. 2016;5(430). DOI:10.1186/s40064-016-2058-z.
   PubMedGoogle Scholar
• Zhou SJ, Wang SQ, Ma YY, et al. Association of proton pump inhibitors with the occurrence of gut-derived bacteraemia in patients with haematological malignancy after chemotherapy. Hematology. 2016;21(6):332–337. .
   PubMed Web of Science ®Google Scholar
• Steinway SN, Biggs MB, Loughran TP Jr, et al. Inference of network dynamics and metabolic interactions in the gut microbiome. PLoS Comput Biol. 2015;11(5):e1004338.
   PubMedGoogle Scholar
• Sorg JA, Sonenshein AL. Bile salts and glycine as cogerminants for Clostridium difficile spores. J Bacteriol. 2008;190:2505–2512.
   PubMed Web of Science ®Google Scholar
• Heard SR, Wren B, Barnett MJ, et al. Clostridium difficile infection in patients with haematological malignant disease: risk factors, faecal toxins and pathogenic strains. Epidem Inf. 1988;100(1):63–72.
   PubMed Web of Science ®Google Scholar
• Canitano A, Iessi E, Spugnini EP, et al. Proton pump inhibitors induce a caspase-independent antitumor effect against human multiple myeloma. Cancer Lett. 2016;376(2):278–283.
   PubMed Web of Science ®Google Scholar
• Chen CH, Lin HC, Lin HL, et al. Proton pump inhibitor usage and the associated risk of pneumonia in patients with chronic kidney disease. J Microbiol Immunol Infect. 2015;48(4):390–396.
   PubMedGoogle Scholar
• Pappas M, Jolly S, Vijan S. Defining appropriate use of proton-pump inhibitors among medical inpatients. J Gen Intern Med. 2016;31(4):364–371.
   PubMed Web of Science ®Google Scholar